孟鲁司特钠治疗哮喘-慢性阻塞性肺疾病重叠综合征的临床效果

Clinical Effect of Montelukast Sodium in the Treatment of Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome

目的探讨孟鲁司特钠治疗哮喘-慢性阻塞性肺疾病重叠综合征的临床效果。方法选取普洱市人民医院2017年3月至2018年3月收治的92例哮喘—慢性阻塞性肺疾病重叠综合征患者,随机分为A组和B组,每组46例。B组接受常规疗法治疗,A组在常规疗法基础上联合孟鲁司特钠治疗,两组均治疗2周。观察并比较两组临床疗效、用力呼气量(FVC)、1秒用力呼气容积(FEV1)和动脉血氧分压(PaO2)水平。结果A组总有效率为95.65%,高于B组的80.43%,差异均有统计学意义(P<0.05)。A组FVC、FEV1、PaO2水平均高于B组,差异均有统计学意义(P<0.05)。结论哮喘-慢性阻塞性肺疾病重叠综合征患者治疗中运用孟鲁司特钠,可获得非常理想的临床效果,在改善患者血气指标方面的优势也比较明显。

Objective To investigate the clinical effect of montelukast sodium in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome.Methods 92 patients with asthma-chronic obstructive pulmonary disease overlap syndrome who were admitted to the Pu'er People's Hospital from March 2017 to March 2018 were randomly divided into group A and group B,46 cases each.Group B received conventional therapy,and group A was treated with montelukast sodium on the basis of conventional therapy.Both groups were treated for 2 weeks.The clinical efficacy,FVC,FEV1 and PaO2 levels were observed and compared between the two groups.Results The total effective rate of group A was 95.65%,which was higher than that of group B(80.43%).The difference was statistically significant(P<0.05).The levels of FVC,FEV1 and PaO2 in group A were higher than those in group B,and the differences were statistically significant(P<0.05).Conclusion The use of montelukast sodium in the treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome can achieve very good clinical results,and the advantages in improving patients'blood gas index are also obvious.